KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lantronix (LTRX) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Lantronix (LTRX) over the last 17 years, with Sep 2025 value amounting to $22.2 million.

  • Lantronix's Cash & Equivalents fell 15.93% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year decrease of 15.93%. This contributed to the annual value of $20.1 million for FY2025, which is 23.40% down from last year.
  • Latest data reveals that Lantronix reported Revenue - Interest and Investment Income of $29.5 million as of Q1 2017, which was up 6.36% from $27.8 million recorded in Q2 2016.
  • Over the past 5 years, Lantronix's Cash & Equivalents peaked at $36.4 million during Q4 2021, and registered a low of $6.8 million during Q4 2022.
  • Moreover, its 2-year median value for Revenue - Interest and Investment Income was $28.7 million (2016), whereas its average is $28.7 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 377.16% in 2021, then plummeted by 81.29% in 2022.
  • Lantronix's Revenue - Interest and Investment Income (Quarterly) stood at $27.8 million in 2016, then followed by $29.5 million in 2017.
  • Its Cash & Equivalents stands at $22.2 million for Q3 2025, versus $20.1 million for Q2 2025 and $20.0 million for Q1 2025.